The deal between Roche and Prothena announced on Wednesday 12/11/2013 values the antibody PRX002, which targets the alpha-synuclein protein thought to be behind the formation of Lewy bodies and part of the pathology if the disease, at $600 million.
This is great news for everyone in the Parkinson's space at it shows that there is interest from "big Pharma" in something other than small molecule dopamine replacement strategies, and in particular more "biological" approaches"
Thursday, December 12, 2013
Wednesday, December 11, 2013
ACS Publication C&EN News publishes piece on link between Parkinson's and pesticide
There's an interesting news article on the (strong) link between Pesticides and Parkinson's disease published in the 11/25 edition of Chemistry and Engineering News, the popular magazine publication of the American Chemical Society.
Friday, November 22, 2013
Seeking Alpha Features ISCO
After the posting of our terrific 3rd quarter performance and discussing the important milestones coming up in the near future, International Stem Cell Corporation has once again been featured on Seeking Alpha, one of the most important investor-centric websites.
Follow the link below to read the full article.
Tuesday, November 5, 2013
American Association for the Study of Liver Diseases selects ISCO's presentation for special praise
The American Association for the Study of Liver Diseases (AASLD) has selected ISCO's presentation, titled "Human parthenogenetic stem cell-derived hepatocyte transplantation controls serum bilirubin in Gunn rats" as a Presidential Poster of Distinction at The Liver Meeting, AASLD'S 64th Annual Meeting in Washington,DC,Novemberl-November5,2013
The presentation authors are Dr. Alina Ostrowska, Dr. Larisa Agapova, Tiffany Chu, Dr. Trudy Christiansen-Weber and Dr. Ruslan Semechkin all of International Stem Cell Corporation, Carlsbad, CA, USA
Background:
Extensive studies indicate that pluripotent stem cells are a highly promising
alternative source of histocompatible cells for cell replacement therapy.
Hepatocyte-like cells (HLCs) derived from human parthenogenetic stem cells
(hpSCs) might be transplanted to treat a wide array of metabolic liver diseases including CN1
(Crigler-Najjar syndrome type I). CN1 is the paradigm of
inherited liver-based metabolic disorders in that the host liver is lacking one
hepatic enzyme - UGT1A1, which is essential for the conjugation and excretion
of bilirubin. To obtain ultimate proof that differentiation has been achieved,
following the preliminary evaluation in
vitro, we tested hepatocyte-like cells in
vivo using an accurate animal model of CN1, the Gunn rats which accumulate
toxic plasma levels of unconjugated bilirubin. Methods: Highly enriched populations of definitive endoderm were
generated from hpSCs in a novel 3D-differentiation system and then induced to
differentiate towards HLCs. The final cells were characterized by using
expression profiling including RT-qPCR for dynamic expression of the hepatic
lineage genes, immunohistochemistry and FACS analysis to demonstrate
hepatocyte-specific markers, drug metabolism assays to determine the activity
of CYP450s as well as a luminescent method for measuring UGT activity profile. Production
of liver-specific proteins in the culture medium was simultaneously measured by
quantitative ELISA. To evaluate engraftment and functional repopulation in
vivo, CFSE-labeled hpHC were injected (10x106 per animal) into
the spleen of 4-6 week old Gunn rats. Blood serum samples of tested animals
were evaluated for indirect bilirubin levels 4, 8 and 19 weeks
post-transplantation. Liver tissue samples were embedded in OCT compound and
snap frozen, until cryosectioning. Results:
CFSE-labeled HLCs transferred into the spleen were shown to migrate into the
liver. Multiple engrafted cells were observed in the periportal regions of the
liver lobules and formed morphologically distinct aggregates. The overall liver
structure appeared undamaged without signs of inflammation, fibrosis or tumor.
Significant decrease and long-term stabilization of bilirubin levels was
demonstrated in the serum of tested animals in comparison with sham-treated
controls. Although by week 19th serum indirect bilirubin was not
normalized in transplanted animals, it resulted in an average 70% reduction
compared with pretreatment levels. Conclusion:
This pre-clinical study describes important supportive evidence of the potential
efficacy and safety of hpSC-derived hepatocytes which might constitute an
easily available source to obtain a large number of transplantable cells for
regenerative treatments of CN1. In the long-term,
experience with HLCs transplantation for CN1 can be used to develop therapeutic
strategies for more common inherited liver diseases.
Monday, November 4, 2013
UC San Diego receives $100 Million gift to launches Sanford Stem Cell Clinical Center
San Diego, Calif. 11/4/13
Good news for UCSD, the Sanford Consortium for Regenerative Medicine and the local stem cell community at large, businessman and philanthropist T. Denny Sanford commits $100 million to the creation of the Sanford Stem Cell Clinical Center at the University of California, San Diego.
See the following link for more details.
Thursday, October 3, 2013
Agora Financial feature ISCO again.
ISCO featured in AGORA Financial's "Breakthrough Technology Alert"
With all the news about BioTime, it's important not to forget that International Stem Cell Corp. (OTCBB:ISCO) is also performing very important work in the stem cell arena.
In October, Dr. Ruslan Semechkin, ISCO's chief scientific officer, will be presenting data from the company's Parkinson's disease program at the American Neurological Association's 2013 annual meeting. The presentation will include new data on the fate of ISCO's parthenogenetic neural stem cells after injection in nonhuman primates and, importantly, information on the mechanisms of action for this potential therapy.
As you know, a first-ever Phase 1 trial of ISCO's therapy is set to begin soon. ISCO is also dirt-cheap at today's prices, considering the technology it owns and the potential it could unlock.
Today, ISCO stock trades for 15 cents a share, and the company's market cap is less than $20 million. The initiation of a Phase 1 trial in humans, and especially good data from that trial, will raise ISCO's profile considerably. The trials are expected to begin in the middle of 2014. Investors should take note.
Ad lucrum per scientia (toward wealth through science),
Ray Blanco
Monday, September 16, 2013
Union Tribune Features International Stem Cell's leadership in Parkinson's dieases
ISCO is in the news again. This time its the San Diego Union Tribune that is featuring ISCO's progress in its Parkinson's diease program and the collaboration with Duke University.
Read the whole feature here.
Thursday, September 5, 2013
Agora Financial Features ISCO in latest edition of Breakthough Technology Alert newletter
Breakthrough Technology Alert writer Ray Blanco features ISCO in his latest newsletter. I've copied a little of the text below (with the permission of the author)
--------------------------------------------------------------------------------------------
September 4, 2013
Important News: Stem Cell Specialists Moving Into Clinical Trials
Dear Breakthrough Technology Alert Reader,
ISCO Enters Into Clinical Agreement
International Stem Cell Corp. (OTCBB: ISCO) is going to be entering clinical trials soon. The company is developing its unique, ethical human parthenogenetic neural stem cell (hPNSC) technology into a treatment for Parkinson's disease................
You'll have to login here to read the whole post breakthroughtechnologyalert.agorafinancial.com
Thursday, August 22, 2013
International Stem Cell Corporation Enters into Clinical Research Agreement for Parkinson’s Disease Program
CARLSBAD, CA – (Marketwired) – 08/21/13 – International
Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a
California-based biotechnology company developing novel stem cell-based
therapies, announced today that it has entered into a master clinical research agreement
with Duke University to conduct clinical trials research in Parkinson’s disease
using ISCO’s innovative neural stem cell product.
Mark Stacy, M.D., Vice Dean for Clinical Research,
Neurology at Duke University School of Medicine and an internationally
recognized leader in the field of Movement Disorders, including Parkinson’s
disease, will be the study’s principal investigator. The research will be
coordinated by the Duke Clinical
Research Institute (DCRI), the world's largest academic clinical
research organization, which is internationally recognized for conducting
groundbreaking clinical trials.
“We are pleased
to have the opportunity to conduct the clinical trials related to ISCO’s investigation stem cell therapy in Parkinson’s disease patients,” said Stacy.
“Duke has an exceptional clinical trials team and we look forward to
characterizing and understanding the safety and efficacy profile of this agent
in the clinical trials setting.”
“We’re tremendously excited to be working with such a world-class
clinical research organization as Duke University,” commented Dr. Ruslan
Semechkin, Vice President of Research and Development at International Stem
Cell Corporation. “Dr. Stacy and his team have made numerous significant
contributions in the field of Parkinson’s disease research which together with
Duke’s extensive clinical expertise in cell therapy clinical trials and the
extensive patient population, gives us an outstanding
opportunity to evaluate our revolutionary stem cell therapy.”
Stacy has extensive clinical trials experience,
primarily involving neuro-protective and neuro-regenerative therapies and
developing biomarkers for early diagnosis in Parkinson’s disease. He has
published more than 100 peer-reviewed scientific papers in the field and has
served as an advisor to a number of companies. He has participated in more than
100 clinical trials.
ISCO’s Parkinson’s disease program uses human parthenogenetic
neural stem cells (hPNSC), a novel therapeutic cellular product derived from the
company’s proprietary histocompatible human pluripotent stem cells. The hPNSC
are self-renewing mulitpotent cells that are precursors for the major cells of
the central nervous system. The ability of hPNSC to (1) differentiate into
dopaminergic neurons and (2) express neurotrophic factors such as glial derived
neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to
protect the nigrostriatal system, offers a new and revolutionary opportunity for
the treatment of Parkinson’s disease, especially in cases where current dopamine-replacement
approaches fail to adequately control the symptoms.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the
therapeutic applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem cells from
unfertilized oocytes (eggs) hence avoiding ethical issues associated with the
use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous stem
cell line that can be a source of therapeutic cells for hundreds of millions of
individuals of differing genders, ages and racial background with minimal
immune rejection after transplantation. hpSCs offer the potential to create the
first true stem cell bank, UniStemCell™. ISCO also produces and markets
specialized cells and growth media for therapeutic research worldwide through
its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem
cell-based skin care products through its subsidiary Lifeline Skin Care
(www.lifelineskincare.com). More information is available at
www.internationalstemcell.com.
Forward-looking Statements
Statements pertaining to anticipated developments, the
potential benefits of research programs and products, and other opportunities
for the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that are not
historical fact (including, but not limited to statements that contain words
such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should
also be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, regulatory
approvals, need and ability to obtain future capital, application of capital
resources among competing uses, and maintenance of intellectual property
rights. Actual results may differ materially from the results anticipated in
these forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update forward-looking statements.
To receive ongoing corporate communications via email,
visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for
company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation
and www.twitter.com/intlstemcell
Contacts:
International
Stem Cell Corporation
Dr.
Simon Craw, Executive Vice President
Phone:
760-940-6383
Email:
ir@intlstemcell.com
Dr.
Ruslan Semechkin, Vice President, R&D
Phone:
760-940-6383
Email:
ras@intlstemcell.com
Investor
Relations:
MZ
Group
Mark
McPartland
Senior
Vice President
Phone:
212-301-7130
Email:
markmcp@mzgroup.us
Monday, August 12, 2013
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation
NEW YORK, NY, Aug 06, 2013 (Marketwired via COMTEX) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on International Stem Cell Corporation (OTCQB: ISCO).
The full 72-page report is available on Crystal Research Associates' website at http://www.crystalra.com/research-library/international-stem-cell-corporation-isco/
International Stem Cell Corporation Announces Second Quarter 2013 Financial Results
Will host conference call at 11 am ET
on August 9, 2013
CARLSBAD, CA - (Marketwired) - August 8, 2013, International
Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com)
(“ISCO” or “the Company”), a California-based biotechnology company developing
novel stem cell based therapies and biomedical products, today announced
financial results for the three and six months ended June 30, 2013.
Q2 2013 Highlights:
·
Revenues increased 38% to $1.46 million over
the second quarter of 2012, with Lifeline Cell Technologies sales up 40% and
Lifeline Skin Care sales up 36%. Gross
margin improved by 600 basis points to 77%
·
Cash burn, excluding capital expenditures
and patent costs, for the first six months of 2013 reduced by 16% compared to
the same period of 2012
·
In preparation for the IND-enabling studies
and after discussion with the FDA office of Cellular, Tissue and Gene Therapies,
ISCO’s R&D team commenced large scale manufacturing of its neural stem cell
product using the previously disclosed methodology
·
Results demonstrating the safety of its novel
cellular replacement and neuroprotective therapy in a primate model of
Parkinson’s disease (PD) were presented at the American Society of Gene &
Cell Therapy meeting in Salt Lake City, UT and the International Society of
Stem Cell Research in Boston, MA
·
Lifeline Skin Care further expanded into the
Asian skin care market by signing distribution agreements to sell its branded
anti-aging skin care products in Thailand and Vietnam.
“We continue to focus our research and development
efforts on our Parkinson’s disease program. We made further progress in demonstrating
the safety of our novel approach of using neural stem cells derived from our
histocompatible stem cells to provide neuroprotective benefits and replace
dying neurons, moving the program closer to the clinic,” stated Dr. Andrey
Semechkin, ISCO’s CEO and Co-chairman.
“I am also pleased to report significant growth in sales
from both subsidiaries, demonstrating that our sales and marketing strategies
are working. This growth resulted in a considerable
reduction in our net cash burn rate,” Dr. Semechkin concluded.
Three Months Ended June 30,
2013
Revenue
for the three months ended June 30, 2013 was $1.46 million, an increase of
approximately 38% compared to $1.06 million for the same period in 2012. Sales for Lifeline Skin
Care (LSC) and Lifeline Cell Technology (LCT) increased by 36% and 40%,
respectively. LSC and LCT accounted for 49% and 51% of total revenue,
respectively, in the three months ended June 30, 2013.
Cost
of sales was $0.33 million, or 23% of revenue, compared to $0.31 million or 29%
of revenue in the same period a year ago. Gross margins improved as a result of
efficiencies in the manufacturing and supply chain management and increased
sales contribution from higher margin products.
General
and administrative expenses declined 5% to $1.67 million, driven primarily by
lower personnel-related expenses resulting from lower headcount, lower
stock-based compensation expenses and lower professional and corporate expenses.
Marketing expenses increased 24% compared to the second quarter of 2012 to
$0.68 million, reflecting higher spending on advertising and promotions for its
skin care business.
Six Months Ended June 30,
2013
Revenue
for the six months ended June 30, 2013 and 2012 was $2.74 million and $2.13
million, respectively. LCT contributed $1.38 million, up 30% from the same
period in 2012 and LSC contributed $1.36 million, up 27% from the same period
in 2012.
Cost
of sales for the six months ended June 30, 2013 was $0.66 million or 24% of
revenue, compared to $0.64 million or 30% of revenue for the same period in
2012 as a result of continued improvements in efficiency and effectiveness in
manufacturing and the management of supply chain in Lifeline Skin Care as well
as a shift in sales mix from lower to higher margin products in Lifeline Cell
Technology. Gross profit and gross
margin for the first six months of 2013 were $2.08 million and 76% compared to
$1.50 million and 70%, respectively, in 2012.
Cash
and cash equivalents totaled $0.65 million at June 30, 2013, essentially
unchanged from $0.65 million as of December 31, 2012. Cash outflows from
operations for the first six months of 2013 were $2.89 million, down from $3.46
million in the corresponding period in 2012. The Company received approximately
$3.27 million, net of stock issuance costs, from the issuance of 16,325,000
shares of common stock in the first six months of 2013. The Company invested
approximately $0.37 million in capital and patent expenditures in the first six
months of 2013 compared to $0.45 million in the same period in 2012.
As
previously announced, subsequent to the end of the second quarter of 2013, the
Company completed a financing transaction under an effective Form S-1
Registration Statement filed with the U.S. Securities and Exchange Commission
raising approximately $2.50 million in net proceeds.
Conference Call and
Webcast Details:
Date: Friday,
August 9, 2013
Time: 11:00
a.m. Eastern Time
Conference
Call Dial-in Numbers
Participants
from US Domestic: 1
877 317-6776
Participants
from International: 1
412 317-6776
Conference
ID: 10032411
Webcast
link: http://webcast.mzvaluemonitor.com/Cover.aspx?PlatformId=1545
Replay
of the conference call will be available for one week following 1 hour after
the end of the conference call through August 16, 2013 at 11:00 am ET.
Teleconference
Replay Details:
US
Domestic: 1-877-344-7529
International: 1-412-317-0088
Conference
ID: 10032411
About
International Stem Cell Corporation
International Stem Cell Corporation is focused on the
therapeutic applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis,
results in the creation of pluripotent human stem cells from unfertilized
oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of therapeutic
cells for hundreds of millions of individuals of differing genders, ages and
racial background with minimal immune rejection after transplantation. hpSCs
offer the potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for therapeutic
research worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products through its
subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is
available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate
communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for
company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation
and www.twitter.com/intlstemcell
Safe
harbor statement
Statements pertaining to anticipated developments,
expected changes in R&D expenses, progress of research and development, potential
sales growth, new products and distribution channels and other opportunities
for the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that are not
historical fact (including, but not limited to statements that contain words
such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should
also be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements and
as such should be evaluated together with the many uncertainties that affect
the company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange Commission filings.
The company disclaims any intent or obligation to update forward-looking
statements.
International Stem Cell Corporation
and Subsidiaries
(A
Development Stage Company)
Condensed
Consolidated Balance Sheets
(in thousands,
except share data)
(Unaudited)
|
|
|
|
|
|
June 30, |
December 31, |
|
Assets |
|
|
|
Cash and cash
equivalents............................................................................................................................. |
$ 654 |
$ 654 |
|
Accounts receivable, net of allowance for doubtful
accounts of $26 and $4 at June 30, 2013 and December 31, 2012,
respectively............................................................................................................. |
454 |
273 |
|
Inventory, net.................................................................................................................................................... |
1,370 |
1,199 |
|
Prepaid expenses and other current assets................................................................................................... |
663 |
456 |
|
Restricted cash.................................................................................................................................................. |
50 |
— |
|
|
|
|
|
Total current assets................................................................................................................................ |
3,191 |
2,582 |
|
Property and equipment, net.......................................................................................................................... |
928 |
1,134 |
|
Intangible assets, net........................................................................................................................................ |
1,947 |
1,634 |
|
Deposits and other assets................................................................................................................................ |
32 |
20 |
|
|
|
|
|
Total assets............................................................................................................................................. |
$ 6,098 |
$ 5,370 |
|
|
|
|
|
Liabilities, Redeemable Preferred Stock and
Stockholders’ Equity (Deficit) |
|
|
|
Accounts payable............................................................................................................................................. |
$ 743 |
$ 969 |
|
Accrued liabilities.............................................................................................................................................. |
1,389 |
730 |
|
Deferred revenue.............................................................................................................................................. |
172 |
233 |
|
Related party payable..................................................................................................................................... |
22 |
5 |
|
Advances........................................................................................................................................................... |
250 |
250 |
|
|
|
|
|
Total current liabilities........................................................................................................................... |
2,576 |
2,187 |
|
|
|
|
|
Convertible Redeemable Series G Preferred stock,
$0.001 par value, 5,000,000 shares were authorized, issued and outstanding at
June 30, 2013 and December 31, 2012, liquidation preferences of $5,000
at June 30, 2013 and December 31, 2012........................................................................................................ |
4,941 |
4,941 |
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
Stockholders’ Equity (Deficit) |
|
|
|
Series D Preferred stock, $0.001 par value, 50
shares authorized, 43 issued and outstanding at June 30, 2013 and
December 31, 2012, liquidation preferences of $4,320 at June 30,
2013 and December 31, 2012............................................................................................................................................... |
— |
— |
|
Series B Preferred stock, $0.001 par value,
5,000,000 shares authorized, 300,000 issued and outstanding at June 30, 2013
and December 31, 2012, liquidation preferences of $393 and $385 at June
30, 2013 and December 31, 2012, respectively...................................................................................... |
— |
— |
|
Series C Preferred stock, $0.001 par value,
3,000,000 shares authorized, 0 and 2,000,000 issued and outstanding at June
30, 2013 and December 31, 2012, respectively, liquidation preferences of
$0 and $2,507 at June 30, 2013 and December 31, 2012, respectively........................................................... |
— |
2 |
|
Common stock, $0.001 par value, 300,000,000 shares
authorized, 112,590,815 and 87,388,815 issued and outstanding at June 30,
2013 and December 31, 2012, respectively................................................... |
113 |
87 |
|
Additional paid-in capital.......................................................................................................................................... |
74,173 |
69,945 |
|
Deficit accumulated during the development stage................................................................................... |
(75,705 ) |
(71,792 ) |
|
|
|
|
|
Total stockholders’ equity (deficit)............................................................................................................... |
(1,419 ) |
(1,758 ) |
|
|
|
|
|
Total liabilities, redeemable preferred stock and
stockholders’ equity (deficit).................................... |
$ 6,098 |
$ 5,370 |
|
|
|
|
International Stem Cell Corporation
and Subsidiaries
(A
Development Stage Company)
Condensed
Consolidated Statements of Operations
(in
thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
Three Months Ended |
Six Months Ended |
Inception |
||
|
|
2013 |
2012 |
2013 |
2012 |
2013 |
|
Revenues |
|
|
|
|
|
|
Product sales |
$ 1,457 |
$ 1,056 |
$ 2,742 |
$ 2,133 |
$ 14,940 |
|
Royalties and license |
— |
— |
— |
— |
135 |
|
|
|
|
|
|
|
|
Total revenue |
1,457 |
1,056 |
2,742 |
2,133 |
15,075 |
|
|
|
|
|
|
|
|
Development expenses |
|
|
|
|
|
|
Cost of sales |
329 |
313 |
663 |
637 |
5,269 |
|
Research and development |
974 |
865 |
1,695 |
1,802 |
23,588 |
|
Marketing |
679 |
548 |
1,191 |
1,044 |
7,130 |
|
General and administrative |
1,667 |
1,755 |
3,099 |
3,794 |
42,227 |
|
|
|
|
|
|
|
|
Total development expenses |
3,649 |
3,481 |
6,648 |
7,277 |
78,214 |
|
|
|
|
|
|
|
|
Loss from development activities |
(2,192 ) |
(2,425 ) |
(3,906 ) |
(5,144 ) |
(63,139 ) |
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
Settlement with related company |
— |
— |
— |
— |
(93 ) |
|
Miscellaneous expense |
(18 ) |
(56 ) |
(20 ) |
(54 ) |
(265 ) |
|
Dividend income |
— |
— |
— |
— |
94 |
|
Interest expense |
— |
— |
— |
— |
(2,225 ) |
|
Sublease income |
10 |
4 |
13 |
7 |
329 |
|
Change in market value of warrants |
— |
— |
— |
38 |
(1,357 ) |
|
|
|
|
|
|
|
|
Total other income (expense), net |
(8 ) |
(52 ) |
(7) |
(9 ) |
(3,517 ) |
|
|
|
|
|
|
|
|
Loss before income taxes |
(2,200 ) |
(2,477 ) |
(3,913 ) |
(5,153 ) |
(66,656 ) |
|
Provision for income taxes |
— |
— |
— |
— |
7 |
|
|
|
|
|
|
|
|
Net loss |
$ (2,200 ) |
$ (2,477 ) |
$ (3,913 ) |
$ (5,153 ) |
$ (66,663 ) |
|
|
|
|
|
|
|
|
Deemed dividend on preferred stock |
— |
— |
— |
(1,375 ) |
(1,375 ) |
|
Dividends on preferred stock |
— |
(139 ) |
— |
(222 ) |
(8,097 ) |
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders |
$ (2,200 ) |
$ (2,616 ) |
$ (3,913 ) |
$ (6,750 ) |
$ (76,135 ) |
|
|
|
|
|
|
|
|
Net loss per common share-basic and diluted |
$ (0.02 ) |
$ (0.03 ) |
$ (0.04 ) |
$ (0.08 ) |
|
|
|
|
|
|
|
|
|
Weighted average shares-basic and diluted |
112,410 |
87,106 |
108,013 |
84,446 |
|
|
|
|
|
|
|
|
Contacts:
International
Stem Cell Corporation
Dr.
Simon Craw, Executive Vice President of Business Development
Phone:
760-940-6383
Email:
ir@intlstemcell.com
Investor
Relations:
MZ
Group
Mark
McPartland
Senior
Vice President
Phone:
212-301-7130
Email:
markmcp@mzgroup.us
Web:
www.mzgroup.us
Subscribe to:
Posts (Atom)